Skip to Content


New Combination Improves Survival for Metastatic Breast Cancer Patients

Conquest - Spring 2012

In an international Phase III randomized study known as BOLERO-2, everolimus combined with the hormonal therapy exemestane has dramatically improved progression-free survival for women with metastatic breast cancer.

Everolimus, an immunosuppressant agent first used to prevent rejection of organ transplants, also has antiangiogenic properties that prohibit a tumor from forming its own vascular system.

Gabriel Hortobagyi, M.D., says results of an international 
Phase III study of the combination of everolimus with the 
hormonal therapy exemestane are "highly significant."
Photo: John Smallwood

The 724 metastatic breast cancer patients enrolled in the trial were all post-menopausal, had hormone receptor-positive disease and evidence of progressive disease. The median age was 62. The study’s primary endpoint was progression-free survival.

In patients receiving the everolimus combination, researchers found a progression-free survival of 7.4 months, compared to 3.2 months in those who took exemestane alone, a finding described as “highly significant.”

The clinical benefit rate — complete responses, partial responses and stability exceeding six months — was 50.5% in those in the combination arm, compared to 25.5% in those who received hormone therapy alone.

“Over the years, our treatment approach for such women with metastatic breast cancer has been sequential use of as many hormone therapies as possible, keeping metastatic disease under control for as long as possible,” says Gabriel Hortobagyi, M.D., professor and chair of the Department of Breast Medical Oncology.

“These findings may allow us to change our approach. In this group of heavily pre-treated patients, all of whom progressed on prior endocrine therapy, the addition of everolimus resulted in significant prolongation of progression-free survival and an improved response rate with only modest toxicity.”

Reported in the Feb. 9, 2012, edition of the New England Journal of Medicine. 

Also reported in December 2011 at the 34th Annual Meeting of the Cancer Therapy and Research Center-American Association for Cancer Research San Antonio Breast Cancer Symposium.

Resources: Metastatic Breast Cancer

Care to Comment?

Email the editor to comment on a story or offer suggestions on topics you'd like to see covered in future issues of Conquest and Annual Report.

Make a difference

Your gift to MD Anderson makes a difference in the lives of cancer patients by supporting innovative patient care, research, education and prevention programs. You can Donate Now or learn more at myGiving to MD Anderson.

© 2015 The University of Texas MD Anderson Cancer Center